NASDAQ:OPTNOptiNose Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding OptiNose Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $6.42 +0.71 (+12.43 %) (As of 08/4/2020 04:00 PM ET) Add Compare Share Today's Range$5.84Now: $6.42▼$6.7150-Day Range$4.12MA: $5.55▼$7.4452-Week Range$3.28Now: $6.42▼$11.66Volume847,702 shsAverage Volume605,228 shsMarket Capitalization$294.74 millionP/E RatioN/ADividend YieldN/ABeta0.83 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps. It is also developing XHANCE, which is in Phase IIIb clinical trial for the treatment of chronic sinusitis; and OPN-300 for the treatment of Prader-Willi syndrome, a rare genetic obesity disorder, as well as autism spectrum disorder. The company has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail (sumatriptan nasal powder) to treat migraine in adults; and Inexia Limited to develop, manufacture, import, and sale products containing orexin receptor agonist and/or orexin receptor positive modulator molecules for the treatment, diagnosis, or prevention of human diseases or conditions associated primarily with orexin receptor agonism and orexin receptor positive modulation. OptiNose, Inc. was founded in 2010 and is headquartered in Yardley, Pennsylvania.Read More Beat the Market (BTM) Rank™ 3.4 Analyst's Opinion Consensus RatingOptiNose has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $21.20, OptiNose has a potential upside of 230.2% from its current price of $6.42.Amount of Analyst CoverageOptiNose has only been the subject of 2 research reports in the past 90 days. Previous Next 2.4 Community Rank Outperform VotesOptiNose has received 225 “outperform” votes. (Add your “outperform” vote.)Underperform VotesOptiNose has received 244 “underperform” votes. (Add your “underperform” vote.)Community SentimentOptiNose has received 52.03% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about OptiNose and other stocks. Vote “Outperform” if you believe OPTN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe OPTN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldOptiNose does not currently pay a dividend.Dividend GrowthOptiNose does not have a long track record of dividend growth. Previous Next 2.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, OptiNose insiders have not sold or bought any company stock.Percentage Held by Insiders38.00% of the stock of OptiNose is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions65.52% of the stock of OptiNose is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for OptiNose are expected to grow in the coming year, from ($2.16) to ($1.31) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of OptiNose is -2.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of OptiNose is -2.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOptiNose has a P/B Ratio of 4.34. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.4Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.69 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:OPTN Previous Symbol CUSIPN/A CIK1494650 Webwww.optinose.com Phone267-364-3500Debt Debt-to-Equity Ratio2.98 Current Ratio4.96 Quick Ratio4.79Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$34.63 million Price / Sales8.51 Cash FlowN/A Price / Cash FlowN/A Book Value$1.48 per share Price / Book4.34Profitability EPS (Most Recent Fiscal Year)($2.63) Net Income$-110,050,000.00 Net Margins-295.66% Return on Equity-209.89% Return on Assets-66.41%Miscellaneous Employees221 Outstanding Shares45,910,000Market Cap$294.74 million Next Earnings DateN/A OptionableNot Optionable $6.42 +0.71 (+12.43 %) (As of 08/4/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive OPTN News and Ratings via Email Sign-up to receive the latest news and ratings for OPTN and its competitors with MarketBeat's FREE daily newsletter. OptiNose (NASDAQ:OPTN) Frequently Asked Questions How has OptiNose's stock been impacted by COVID-19 (Coronavirus)? OptiNose's stock was trading at $5.06 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, OPTN shares have increased by 26.9% and is now trading at $6.42. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of OptiNose? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OptiNose in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for OptiNose. How were OptiNose's earnings last quarter? OptiNose Inc (NASDAQ:OPTN) announced its earnings results on Tuesday, August, 4th. The company reported ($0.56) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.56). OptiNose had a negative return on equity of 209.89% and a negative net margin of 295.66%. View OptiNose's earnings history. What price target have analysts set for OPTN? 5 Wall Street analysts have issued 1 year price objectives for OptiNose's stock. Their forecasts range from $17.00 to $25.00. On average, they anticipate OptiNose's share price to reach $21.20 in the next year. This suggests a possible upside of 230.2% from the stock's current price. View analysts' price targets for OptiNose. Has OptiNose been receiving favorable news coverage? Headlines about OPTN stock have been trending somewhat negative recently, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. OptiNose earned a media sentiment score of -1.0 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 5.0 out of 10, meaning that recent press coverage is somewhat likely to have an effect on the company's share price in the next several days. View the latest news about OptiNose. Are investors shorting OptiNose? OptiNose saw a increase in short interest in July. As of July 15th, there was short interest totaling 7,090,000 shares, an increase of 7.3% from the June 30th total of 6,610,000 shares. Based on an average trading volume of 577,900 shares, the days-to-cover ratio is currently 12.3 days. Approximately 29.1% of the company's stock are sold short. View OptiNose's Current Options Chain. Who are some of OptiNose's key competitors? Some companies that are related to OptiNose include Akero Therapeutics (AKRO), Retrophin (RTRX), VBI Vaccines (VBIV), Phathom Pharmaceuticals (PHAT), I-Mab (ARQT), Arcus Biosciences (RCUS), Amphastar Pharmaceuticals (AMPH), DiaMedica Therapeutics (DMCAF), BioXcel Therapeutics (BTAI), Phibro Animal Health (PAHC), Enanta Pharmaceuticals (ENTA), Athenex (ATNX), Aimmune Therapeutics (AIMT), Rhythm Pharmaceuticals (RYTM) and Generation Bio (GBIO). View all competitors. What other stocks do shareholders of OptiNose own? Based on aggregate information from My MarketBeat watchlists, some companies that other OptiNose investors own include Proteostasis Therapeutics (PTI), Idera Pharmaceuticals (IDRA), Matinas BioPharma (MTNB), Viking Therapeutics (VKTX), Clearside Biomedical (CLSD), Paratek Pharmaceuticals (PRTK), Syndax Pharmaceuticals (SNDX), Coherus Biosciences (CHRS), Ovid Therapeutics (OVID) and Strongbridge Biopharma (SBBP). Who are OptiNose's key executives? OptiNose's management team includes the following people: Mr. Peter K. Miller, CEO & Director (Age 59, Pay $1.02M)Dr. Ramy A. Mahmoud M.D., M.P.H., Pres & COO (Age 55, Pay $743.72k)Mr. Keith Alan Goldan, Chief Financial Officer (Age 49, Pay $603.73k)Mr. Michael F. Marino, Chief Legal Officer & Corp. Sec. (Age 44, Pay $708.26k)Mr. Jonathan Neely, VP of Investor Relations & Bus. Operations When did OptiNose IPO? (OPTN) raised $101 million in an IPO on Friday, October 13th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. Jefferies, Piper Jaffray, BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO. What is OptiNose's stock symbol? OptiNose trades on the NASDAQ under the ticker symbol "OPTN." Who are OptiNose's major shareholders? OptiNose's stock is owned by many different institutional and retail investors. Top institutional investors include Paradigm Capital Management Inc. NY (1.62%), Kornitzer Capital Management Inc. KS (0.20%), SG Americas Securities LLC (0.04%), ProShare Advisors LLC (0.03%) and UBS Group AG (0.01%). Company insiders that own OptiNose stock include Avista Capital Partners Ii Gp,, Joseph C Scodari, Peter K Miller and Thomas Edward Gibbs. View institutional ownership trends for OptiNose. Which institutional investors are selling OptiNose stock? OPTN stock was sold by a variety of institutional investors in the last quarter, including Kornitzer Capital Management Inc. KS, and UBS Group AG. View insider buying and selling activity for OptiNose. Which institutional investors are buying OptiNose stock? OPTN stock was acquired by a variety of institutional investors in the last quarter, including Paradigm Capital Management Inc. NY, SG Americas Securities LLC, and ProShare Advisors LLC. Company insiders that have bought OptiNose stock in the last two years include Joseph C Scodari, Peter K Miller, and Thomas Edward Gibbs. View insider buying and selling activity for OptiNose. How do I buy shares of OptiNose? Shares of OPTN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is OptiNose's stock price today? One share of OPTN stock can currently be purchased for approximately $6.42. How big of a company is OptiNose? OptiNose has a market capitalization of $294.74 million and generates $34.63 million in revenue each year. The company earns $-110,050,000.00 in net income (profit) each year or ($2.63) on an earnings per share basis. OptiNose employs 221 workers across the globe. What is OptiNose's official website? The official website for OptiNose is www.optinose.com. How can I contact OptiNose? OptiNose's mailing address is 1020 STONY HILL ROAD SUITE 300, YARDLEY PA, 19067. The company can be reached via phone at 267-364-3500 or via email at [email protected] This page was last updated on 8/5/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
